

Chapter 54

Pemphigus

Aimee S. Payne & John R. Stanley

REFERENCES

1. Lever WF: *Pemphigus and Pemphigoid*. Springfield, IL, Charles C. Thomas, 1965
2. Beutner EH, Jordon RE: Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent staining. *Proc Soc Exp Biol Med* **117**:505, 1964
3. Krain LS: Pemphigus. Epidemiologic and survival characteristics of 59 patients, 1955–1973. *Arch Dermatol* **110**:862, 1974
4. Pisanti S et al: Pemphigus vulgaris: Incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. *Oral Surg Oral Med Oral Pathol* **38**:382, 1974
5. Hietanen J, Salo OP: Pemphigus: An epidemiological study of patients treated in Finnish hospitals between 1969 and 1978. *Acta Derm Venereol (Stockh)* **62**:491, 1982
6. Bastuji-Garin S et al: Comparative epidemiology of pemphigus in Tunisia and France: Unusual incidence of pemphigus foliaceus in young Tunisian women. *J Invest Dermatol* **104**:302, 1995
7. Chams-Davatchi C et al: Pemphigus: Analysis of 1209 cases. *Int J Dermatol* **44**:470, 2005
8. Goon AT, Tan SH: Comparative study of pemphigus vulgaris and pemphigus foliaceus in Singapore. *Australas J Dermatol* **42**:172, 2001
9. Langan SM et al: Bullous pemphigoid and pemphigus vulgaris—Incidence and mortality in the UK: Population based cohort study. *BMJ* **337**:a180, 2008
10. Marazza G et al: Incidence of bullous pemphigoid and pemphigus in Switzerland: A 2-year prospective study. *Br J Dermatol* **161**:861, 2009
11. Diaz LA et al: Endemic pemphigus foliaceus (fogo selvagem): II. Current and historical epidemiological aspects. *J Invest Dermatol* **92**:4, 1989
12. Aoki V et al: Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem). *J Investig Dermatol Symp Proc* **9**:34, 2004
13. Lombardi C et al: Environmental risk factors in endemic pemphigus foliaceus (Fogo selvagem). *J Invest Dermatol* **98**:847, 1992
14. Warren SJ et al: The prevalence of antibodies against desmoglein 1 in endemic pemphigus foliaceus in Brazil. Cooperative Group on Fogo Selvagem Research. *New Engl J Med* **343**:23, 2000
15. Diaz LA et al: Anti-desmoglein-1 antibodies in onchocerciasis, leishmaniasis and Chagas disease suggest a possible etiological link to Fogo selvagem. *J Invest Dermatol* **123**:1045, 2004
16. Uzun S et al: Pemphigus in the Mediterranean region of Turkey: A study of 148 cases. *Int J Dermatol* **45**:523, 2006
17. V'lickova-Laskoska MT et al: Epidemiology of pemphigus in Macedonia: A 15-year retrospective study (1990–2004). *Int J Dermatol* **46**:253, 2007
18. Salmanpour R et al: Epidemiology of pemphigus in south-western Iran: A 10-year retrospective study (1991–2000). *Int J Dermatol* **45**:103, 2006
19. Michailidou EZ et al: Epidemiologic survey of pemphigus vulgaris with oral manifestations in northern Greece: Retrospective study of 129 patients. *Int J Dermatol* **46**:356, 2007
20. Ljubojevic S et al: Pemphigus vulgaris: A review of treatment over a 19-year period. *J Eur Acad Dermatol Venereol* **16**:599, 2002
21. Abreu-Velez AM et al: A unique form of endemic pemphigus in northern Colombia. *J Am Acad Dermatol* **49**:599, 2003
22. Tallab T et al: The incidence of pemphigus in the southern region of Saudi Arabia. *Int J Dermatol* **40**:570, 2001
23. Simon DG et al: Pemphigus in Hartford County, Connecticut, from 1972 to 1977. *Arch Dermatol* **116**:1035, 1980
24. Tsankov N et al: Epidemiology of pemphigus in Sofia, Bulgaria. A 16-year retrospective study (1980–1995). *Int J Dermatol* **39**:104, 2000
25. Micali G, Musumeci ML, Nasca MR: Epidemiologic analysis and clinical course of 84 consecutive cases of pemphigus in eastern Sicily. *Int J Dermatol* **37**:197, 1998
26. Metry DW, Hebert AA, Jordon RE: Nonendemic pemphigus foliaceus in children. *J Am Acad Dermatol* **46**:419, 2002
27. Koulu L et al: Human autoantibodies against a desmosomal core protein in pemphigus foliaceus. *J Exp Med* **160**:1509, 1984

28. Stanley JR et al: A monoclonal antibody to the desmosomal glycoprotein desmoglein I binds the same polypeptide as human autoantibodies in pemphigus foliaceus. *J Immunol* **136**:1227, 1986
29. Amagai M, Klaus-Kovtun V, Stanley JR: Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. *Cell* **67**:869, 1991
30. Payne AS et al: Desmosomes and disease: Pemphigus and bullous impetigo. *Curr Opin Cell Biol* **16**:536, 2004
31. Stanley JR, Amagai M: Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. *N Engl J Med* **355**:1800, 2006
32. Amagai M et al: The extracellular domain of pemphigus vulgaris antigen (desmoglein 3) mediates weak homophilic adhesion. *J Invest Dermatol* **102**:402, 1994
33. Chitaev NA, Troyanovsky SM: Direct Ca²⁺-dependent heterophilic interaction between desmosomal cadherins, desmoglein and desmocollin, contributes to cell-cell adhesion. *J Cell Biol* **138**:193, 1997
34. Stanley JR, Klaus Kovtun V, Sampaio SA: Antigenic specificity of fogo selvagem autoantibodies is similar to North American pemphigus foliaceus and distinct from pemphigus vulgaris autoantibodies. *J Invest Dermatol* **87**:197, 1986
35. Ishii K et al: Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. *J Immunol* **159**:2010, 1997
36. Eyre RW, Stanley JR: Identification of pemphigus vulgaris antigen extracted from normal human epidermis and comparison with pemphigus foliaceus antigen. *J Clin Invest* **81**:807, 1988
37. Ding X et al: Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. *J Invest Dermatol* **109**:592, 1997
38. Amagai M et al: The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. *J Am Acad Dermatol* **40**:170, 1999
39. Miyagawa S et al: Late development of antidesmoglein 1 antibodies in pemphigus vulgaris: Correlation with disease progression. *Br J Dermatol* **141**:1084, 1999
40. Schiltz JR, Michel B: Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. *J Invest Dermatol* **67**:254, 1976
41. Anhalt GJ et al: Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. *N Engl J Med* **306**:1189, 1982
42. Rock B, Labib RS, Diaz LA: Monovalent Fab' immunoglobulin fragments from endemic pemphigus foliaceus autoantibodies reproduce the human disease in neonatal Balb/c mice. *J Clin Invest* **85**:296, 1990
43. Amagai M et al: Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. *J Clin Invest* **90**:919, 1992
44. Amagai M et al: Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. *J Clin Invest* **94**:59, 1994
45. Ding X et al: The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic. *J Invest Dermatol* **112**:739, 1999
46. Amagai M et al: Antigen-specific immunoabsorption of pathogenic autoantibodies in pemphigus foliaceus. *J Invest Dermatol* **104**:895, 1995
47. Chowdhury MMU, Natarajan S: Neonatal pemphigus vulgaris associated with mild oral pemphigus vulgaris in the mother during pregnancy. *Br J Dermatol* **139**:500, 1998
48. Kljuic A et al: Desmoglein 4 in hair follicle differentiation and epidermal adhesion: Evidence from inherited hypotrichosis and acquired pemphigus vulgaris. *Cell* **113**:249, 2003
49. Nagasaka T et al: Defining the pathogenic involvement of desmoglein 4 in pemphigus and staphylococcal scalded skin syndrome. *J Clin Invest* **114**:1484, 2004
50. Nguyen VT, Ndoye A, Grando SA: Pemphigus vulgaris antibody identifies pemphaxin. *J Biol Chem* **275**:29466, 2000
51. Evangelista F, Dasher DA, Diaz LA, et al: E-cadherin is an additional immunological target for pemphigus autoantibodies. *J Invest Dermatol* **128**:1710, 2008
52. Wilgram GF, Caulfield JB, Madgic EB: An electron microscopic study of acantholysis and dyskeratosis in pemphigus foliaceus. *J Invest Dermatol* **43**:287, 1964
53. Guedes AC et al: Ultrastructural aspects of mucosae in endemic pemphigus foliaceus. *Arch Dermatol* **138**:949, 2002
54. Hashimoto K, Lever WF: An electron microscopic study on pemphigus vulgaris of the mouth and the skin with special reference to the intercellular cement. *J Invest Dermatol* **48**:540, 1967

55. Diercks GF, Pas HH, Jonkman MF: The ultrastructure of acantholysis in pemphigus vulgaris. *Br J Dermatol* **160**:460, 2009
56. Shimizu A et al: Ultrastructural changes in mice actively producing antibodies to desmoglein 3 parallel those in patients with pemphigus vulgaris. *Arch Dermatol Res* **294**:318, 2002
57. Shimizu A et al: IgG binds to desmoglein 3 in desmosomes and causes a desmosomal split without keratin retraction in a pemphigus mouse model. *J Invest Dermatol* **122**(5):1145-1153, 2004
58. Bystryn JC, Grando SA: A novel explanation for acantholysis in pemphigus vulgaris: The basal cell shrinkage hypothesis. *J Am Acad Dermatol* **54**:513, 2006
59. Wang W, Amagai M, Ishiko A: Desmosome splitting is a primary ultrastructural change in the acantholysis of pemphigus. *J Dermatol Sci* **54**:59, 2009
60. Anhalt GJ et al: Defining the role of complement in experimental pemphigus vulgaris in mice. *J Immunol* **137**:2835, 1986
61. Payne AS et al: Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. *J Clin Invest* **115**:888, 2005
62. Ishii K et al: Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies. *J Invest Dermatol* **128**:939, 2008
63. Futei Y et al: Use of domain-swapped molecules for conformational epitope mapping of desmoglein 3 in pemphigus vulgaris. *J Invest Dermatol* **115**:829, 2000
64. Li N et al: The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem). *J Exp Med* **197**:1501, 2003
65. Hacker-Foegen MK et al: Pathogenicity and epitope characteristics of anti-desmoglein-1 from pemphigus foliaceus patients expressing only IgG1 autoantibodies. *J Invest Dermatol* **121**:1373, 2003
66. Sekiguchi M et al: Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins. *J Immunol* **167**:5439, 2001
67. Boggon TJ et al: C-cadherin ectodomain structure and implications for cell adhesion mechanisms. *Science* **296**:1308, 2002
68. Al-Amoudi A et al: The molecular architecture of cadherins in native epidermal desmosomes. *Nature* **450**:832, 2007
69. Aoyama Y, Kitajima Y: Pemphigus vulgaris-IgG causes a rapid depletion of desmoglein 3 (Dsg3) from the Triton X-100 soluble pools, leading to the formation of Dsg3-depleted desmosomes in a human squamous carcinoma cell line, DJM-1 cells. *J Invest Dermatol* **112**:67, 1999
70. Sato M, Aoyama Y, Kitajima Y: Assembly pathway of desmoglein 3 to desmosomes and its perturbation by pemphigus vulgaris-IgG in cultured keratinocytes, as revealed by time-lapsed labeling immunoelectron microscopy. *Lab Invest* **80**:1583, 2000
71. Calkins CC et al: Desmoglein endocytosis and desmosome disassembly are coordinated responses to pemphigus autoantibodies. *J Biol Chem* **281**:7623, 2006
72. Mao X, Choi EJ, Payne AS: Disruption of desmosome assembly by monovalent human pemphigus vulgaris monoclonal antibodies. *J Invest Dermatol* **129**:908, 2009
73. Koch PJ et al: Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. *J Cell Biol* **137**:1091, 1997
74. Amagai M et al: Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. *Nat Med* **6**:1275, 2000
75. Rivitti EA et al: Pemphigus foliaceus autoantibodies bind both epidermis and squamous mucosal epithelium, but tissue injury is detected only in the epidermis. The Cooperative Group on Fogo Selvagem Research. *J Am Acad Dermatol* **31**:954, 1994
76. Mahoney MG et al: Explanation for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. *J Clin Invest* **103**:461, 1999
77. Wu H et al: Protection of neonates against pemphigus foliaceus by desmoglein 3. *N Engl J Med* **343**:31, 2000
78. Hanakawa Y, Matsuyoshi N, Stanley JR: Expression of desmoglein 1 compensates for genetic loss of desmoglein 3 in keratinocyte adhesion. *J Invest Dermatol* **119**:27, 2002
79. Rocha-Alvarez R et al: Pregnant women with endemic pemphigus foliaceus (Fogo Selvagem) give birth to disease-free babies. *J Invest Dermatol* **99**:78, 1992
80. Berkowitz P et al: p38MAPK inhibition prevents disease in pemphigus vulgaris mice. *Proc Natl Acad Sci U S A* **103**:12855, 2006

81. Waschke J et al: Inhibition of Rho A activity causes pemphigus skin blistering. *J Cell Biol* **175**:721, 2006
82. Sharma P, Mao X, Payne AS: Beyond steric hindrance: The role of adhesion signaling pathways in the pathogenesis of pemphigus. *J Dermatol Sci* **48**:1, 2007
83. Wucherpfennig KW, Strominger JL: Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: A mechanism for MHC-linked susceptibility to human autoimmune diseases [comment]. *J Exp Med* **181**:1597, 1995
84. Pavoni DP et al: Dissecting the associations of endemic pemphigus foliaceus (Fogo Selvagem) with HLA-DRB1 alleles and genotypes. *Genes Immun* **4**:110, 2003
85. Hertl M, Eming R, Veldman C: T cell control in autoimmune bullous skin disorders. *J Clin Invest* **116**:1159, 2006
86. Wucherpfennig KW et al: Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: Charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. *Proc Natl Acad Sci U S A* **92**:11935, 1995
87. Lin MS et al: Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. *J Clin Invest* **99**:31, 1997
88. Hertl M et al: Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3 specific T cell responses in pemphigus vulgaris patients and normals. *J Invest Dermatol* **110**:388, 1998
89. Hertl M et al: Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals. *J Invest Dermatol* **110**:62, 1998
90. Veldman CM et al: T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals. *J Immunol* **172**:3883, 2004
91. Veldman C et al: Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. *J Immunol* **172**:6468, 2004
92. Yamagami J et al: Antibodies to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned from individuals without pemphigus. *J Immunol* **183**:5615, 2009
93. Hacker-Foegen MK, Fairley JA, Lin MS: T cell receptor gene usage in desmoglein-3-specific T lymphocytes from patients with pemphigus vulgaris. *J Invest Dermatol* **121**:1365, 2003
94. Muramatsu T et al: Pemphigus vulgaris exacerbated by exposure to sunlight. *J Dermatol* **23**:559, 1996
95. Reis VM et al: UVB-induced acantholysis in endemic Pemphigus foliaceus (Fogo selvagem) and Pemphigus vulgaris. *J Am Acad Dermatol* **42**:571, 2000
96. Grando SA et al: History and clinical significance of mechanical symptoms in blistering dermatoses: A reappraisal. *J Am Acad Dermatol* **48**:86, 2003
97. Nelson CG et al: Pemphigus vegetans of Hallopeau: Immunofluorescent studies. *Arch Dermatol* **113**:942, 1977
98. Ahmed AR, Blose DA: Pemphigus vegetans. Neumann type and Hallopeau type. *Int J Dermatol* **23**:135, 1984
99. Yoshida K et al: Cutaneous type pemphigus vulgaris: A rare clinical phenotype of pemphigus. *J Am Acad Dermatol* **52**:839, 2005
100. Trattner A et al: Esophageal involvement in pemphigus vulgaris: A clinical, histologic, and immunopathologic study. *J Am Acad Dermatol* **24**:223, 1991
101. Rao PN et al: Study of upper gastrointestinal tract involvement in pemphigus by esophago-gastro-duodenoscopy. *Indian J Dermatol Venereol Leprol* **72**:421, 2006
102. Malik M, Ahmed AR: Involvement of the female genital tract in pemphigus vulgaris. *Obstet Gynecol* **106**:1005, 2005
103. Hale EK, Bystryk JC: Laryngeal and nasal involvement in pemphigus vulgaris. *J Am Acad Dermatol* **44**:609, 2001
104. Espana A et al: Ear, nose and throat manifestations in pemphigus vulgaris. *Br J Dermatol* **156**:733, 2007
105. Hodak E et al: Conjunctival involvement in pemphigus vulgaris: A clinical, histopathological and immunofluorescence study. *Br J Dermatol* **123**:615, 1990
106. Daoud YJ et al: Ocular pemphigus. *J Am Acad Dermatol* **53**:585, 2005
107. Akhyani M et al: Cervicovaginal involvement in pemphigus vulgaris: A clinical study of 77 cases. *Br J Dermatol* **158**:478, 2008
108. Onuma K et al: Pemphigus vulgaris of the vagina—its cytomorphic features on liquid-based cytology and pitfalls: Case report and cytological differential diagnosis. *Diagn Cytopathol* **37**:832, 2009
109. Suami M et al: Keratolysis in a patient with pemphigus vulgaris. *Br J Ophthalmol* **85**:1263, 2001

110. Igawa K, Matsunaga T, Nishioka K: Involvement of UV-irradiation in pemphigus foliaceus. *J Eur Acad Dermatol Venereol* **18**:216, 2004
111. Kano Y et al: Pemphigus foliaceus induced by exposure to sunlight. Report of a case and analysis of photochallenge-induced lesions. *Dermatology* **201**:132, 2000
112. Senear FE, Usher B: An unusual type of pemphigus combining features of lupus erythematosus. *Arch Dermatol Syphilol* **13**:761, 1926
113. Senear FE, Kingery LB: Pemphigus erythematosus. *Arch Dermatol Syphilol* **60**:238, 1949
114. Jablonska S et al: Pathogenesis of pemphigus erythematosus. *Arch Dermatol Res* **258**:135, 1977
115. Amerian ML, Ahmed AR: Pemphigus erythematosus. Senear-Usher syndrome. *Int J Dermatol* **24**:16, 1985
116. Fainaru O et al: Pemphigus vulgaris in pregnancy: A case report and review of literature. *Hum Reprod* **15**:1195, 2000
117. Eyre RW, Stanley JR: Maternal pemphigus foliaceus with cell surface antibody bound in neonatal epidermis. *Arch Dermatol* **124**:25, 1988
118. Avalos-Diaz E et al: Transplacental passage of maternal pemphigus foliaceus autoantibodies induces neonatal pemphigus. *J Am Acad Dermatol* **43**:1130, 2000
119. Hirsch R et al: Neonatal pemphigus foliaceus. *J Am Acad Dermatol* **49**:S187, 2003
120. Kanwar AJ, Dhar S, Kaur S: Further experience with pemphigus in children. *Pediatr Dermatol* **11**:107, 1996
121. Mutasim DF, Pelc NJ, Anhalt GJ: Drug-induced pemphigus. *Dermatol Clin* **11**:463, 1993
122. Korman NJ et al: Drug-induced pemphigus: Autoantibodies directed against the pemphigus antigen complexes are present in penicillamine and captopril-induced pemphigus. *J Invest Dermatol* **96**:273, 1991
123. Ruocco V, Brenner S, Lombardi ML: A case of diet-related pemphigus. *Dermatology* **192**:373, 1996
124. Tur E, Brenner S: Diet and pemphigus. In pursuit of exogenous factors in pemphigus and fogo selvagem. *Arch Dermatol* **134**:1406, 1998
125. Mehta JN, Martin AG: A case of pemphigus vulgaris improved by cigarette smoking. *Arch Dermatol* **136**:15, 2000
126. Nguyen VT et al: Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists. *Arch Dermatol* **140**:327, 2004
127. Iraj F, Yoosefi A: Healing effect of pilocarpine gel 4% on skin lesions of pemphigus vulgaris. *Int J Dermatol* **45**:743, 2006
128. Chernyavsky AI et al: Differential coupling of M1 muscarinic and alpha 7 nicotinic receptors to inhibition of pemphigus acantholysis. *J Biol Chem* **283**:3401, 2008
129. Pullan RD et al: Transdermal nicotine for active ulcerative colitis. *New Engl J Med* **330**:811, 1994
130. Patten SF, Dijkstra JW: Associations of pemphigus and autoimmune disease with malignancy or thymoma. *Int J Dermatol* **33**:836, 1994
131. Udey MC, Stanley JR: Pemphigus: Diseases of anti-desmosomal autoimmunity. *JAMA* **282**:572, 1999
132. Emmerson RW, Wilson-Jones E: Eosinophilic spongiolysis in pemphigus. *Arch Dermatol* **97**:252, 1968
133. Beutner EH et al: Autoantibodies in pemphigus vulgaris. *JAMA* **192**:682, 1965
134. Judd KP, Lever WF: Correlation of antibodies in skin and serum with disease severity in pemphigus. *Arch Dermatol* **115**:428, 1979
135. Chorzelski T, Jablonska S, Blaszczyk M: Immunopathological investigations in the Senear-Usher syndrome (coexistence of pemphigus and lupus erythematosus). *Br J Dermatol* **80**:211, 1968
136. Harman KE et al: The use of two substrates to improve the sensitivity of indirect immunofluorescence in the diagnosis of pemphigus. *Br J Dermatol* **142**:1135, 2000
137. Krasny SA, Beutner EH, Chorzelski TP: Specificity and sensitivity of indirect and direct immunofluorescent findings in the diagnosis of pemphigus. In: *Immunopathology of the Skin*, edited by EH Beutner, TP Chorzelski, V Kumar. New York City, NY, John Wiley and Sons, 1987, pp. 207-247
138. O'Loughlin S, Goldman GC, Provost TT: Fate of pemphigus antibody following successful therapy. Preliminary evaluation of pemphigus antibody determinations to regulate therapy. *Arch Dermatol* **114**:1769, 1978
139. Aberer W et al: Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up. *J Am Acad Dermatol* **16**:527, 1987
140. Amagai M et al: Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. *Br J Dermatol* **140**:351, 1999
141. Amagai M et al: Conformational epitopes of pemphigus antigens (Dsg1 and Dsg3) are calcium dependent and glycosylation independent. *J Invest Dermatol* **105**:243, 1995

142. Cheng SW et al: Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. *Br J Dermatol* **147**:261, 2002
143. Ishii K et al: Development of pemphigus vulgaris in a patient with pemphigus foliaceus: Antidesmoglein antibody profile shift confirmed by enzyme-linked immunosorbent assay. *J Am Acad Dermatol* **42**:859, 2000
144. Komai A et al: The clinical transition between pemphigus foliaceus and pemphigus vulgaris correlates well with the changes in autoantibody profile assessed by an enzyme-linked immunosorbent assay. *Br J Dermatol* **144**:1177, 2001
145. Tsuji Y et al: Clinical and serological transition from pemphigus vulgaris to pemphigus foliaceus demonstrated by desmoglein ELISA system. *Arch Dermatol* **138**:95, 2002
146. Arteaga LA et al: A subset of pemphigus foliaceus patients exhibits pathogenic autoantibodies against both desmoglein-1 and desmoglein-3. *J Invest Dermatol* **118**:806, 2002
147. Carson PJ, Hameed A, Ahmed AR: Influence of treatment on the clinical course of pemphigus vulgaris. *J Am Acad Dermatol* **34**:645, 1996
148. Bystryrn JC, Rudolph JL: Pemphigus. *Lancet* **366**:61, 2005
149. Stanley JR: Therapy of pemphigus vulgaris. *Arch Dermatol* **135**:76, 1999
150. Bystryrn JC, Steinman NM: The adjuvant therapy of pemphigus. An update. *Arch Dermatol* **132**:203, 1996
151. Risser J, Lewis K, Weinstock MA: Mortality of bullous skin disorders from 1979 through 2002 in the United States. *Arch Dermatol* **145**:1005, 2009
152. Ahmed AR, Moy R: Death in pemphigus. *J Am Acad Dermatol* **7**:221, 1982
153. Herbst A, Bystryrn JC: Patterns of remission in pemphigus vulgaris. *J Am Acad Dermatol* **42**:422, 2000
154. Mimouni D et al: Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. *J Am Acad Dermatol* **49**:1059, 2003
155. Seidenbaum M, David M, Sandbank M: The course and prognosis of pemphigus. A review of 115 patients. *Int J Dermatol* **27**:580, 1988
156. Murrell DF et al: Consensus statement on definitions of disease endpoints and therapeutic response for pemphigus. *J Am Acad Dermatol* **58**:1043, 2008
157. Pfütze M et al: Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. *Eur J Dermatol* **17**:4, 2007
158. Rosenbach M et al: Reliability and convergent validity of two outcome instruments for pemphigus. *J Invest Dermatol* **129**:2404, 2008
159. Rosenberg FR, Sanders S, Nelson CT: Pemphigus: A 20-year review of 107 patients treated with corticosteroids. *Arch Dermatol* **112**:962, 1976
160. Hirone T: Pemphigus: A survey of 85 patients between 1970 and 1974. *J Dermatol* **5**:43, 1978
161. Ratnam KV, Phay KL, Tan CK: Pemphigus therapy with oral prednisolone regimens. A 5-year study. *Int J Dermatol* **29**:363, 1990
162. Fine JD: Management of acquired bullous skin diseases. *N Engl J Med* **333**:1475, 1995
163. Harman KE, Albert S, Black MM: Guidelines for the management of pemphigus vulgaris. *Br J Dermatol* **149**:926, 2003
164. Nguyen VT et al: Pemphigus vulgaris IgG and methylprednisolone exhibit reciprocal effects on keratinocytes. *J Biol Chem* **279**:2135, 2004
165. Beissert S et al: A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. *Arch Dermatol* **142**:1447, 2006
166. Chams-Davatchi C et al: Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. *J Am Acad Dermatol* **57**:622, 2007
167. Olszewska M et al: Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. *Am J Clin Dermatol* **8**:85, 2007
168. Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. *Am J Hum Genet* **32**:651, 1980
169. Schaeffeler E et al: Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. *Pharmacogenetics* **14**:407, 2004
170. Reuther LO et al: Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders. The impact of TPMT genotyping in predicting toxicity. *Eur J Clin Pharmacol* **59**:797, 2004
171. Enk AH, Knop J: Mycophenolate mofetil is effective in the treatment of pemphigus vulgaris. *Arch Dermatol* **135**:54, 1999

172. Mimouni D et al: Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. *Arch Dermatol* **139**:739, 2003
173. Roche Pharmaceuticals: Cellcept prescribing information. 2007
174. Oz HS, Hughes WT: Novel anti-*Pneumocystis carinii* effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. *J Infect Dis* **175**:901, 1997
175. Cummins DL et al: Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. *J Am Acad Dermatol* **49**:276, 2003
176. Pasricha JS, Das SS: Curative effect of dexamethasone-cyclophosphamide pulse therapy for the treatment of pemphigus vulgaris. *Int J Dermatol* **31**:875, 1992
177. Kanwar AJ, Kaur S, Thami GP: Long-term efficacy of dexamethasone-cyclophosphamide pulse therapy in pemphigus. *Dermatology* **204**:228, 2002
178. Hayag MV, Cohen JA, Kerdel FA: Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. *J Am Acad Dermatol* **43**:1065, 2000
179. Nousari CH, Brodsky R, Anhalt GJ: Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris. *J Am Acad Dermatol* **49**:148, 2003
180. Heaphy MR, Albrecht J, Werth VP: Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. *Arch Dermatol* **141**:699, 2005
181. Werth VP et al: Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. *Arch Dermatol* **144**:25, 2008
182. Eming R et al: Rituximab exerts a dual effect in pemphigus vulgaris. *J Invest Dermatol* **128**:2850, 2008
183. Joly P et al: A single cycle of rituximab for the treatment of severe pemphigus. *New Engl J Med* **357**:545, 2007
184. Hertl M, Eming R, Borradori L: Rituximab (anti-CD20 monoclonal antibody)—Ultimate or first choice in pemphigus? *Dermatology* **214**:275, 2007
185. Allen KJ, Wolverton SE: The efficacy and safety of rituximab in refractory pemphigus: A review of case reports. *J Drugs Dermatol* **6**:883, 2007
186. Cianchini G et al: Treatment of severe pemphigus with rituximab: Report of 12 cases and a review of the literature. *Arch Dermatol* **143**:1033, 2007
187. Kolstad A et al: *Pneumocystis jirovecii* pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. *Haematologica* **92**:139, 2007
188. Teichmann LL et al: Fatal *Pneumocystis* pneumonia following rituximab administration for rheumatoid arthritis. *Rheumatology* **47**:1256, 2008
189. Yu Z, Lennon VA: Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. *New Engl J Med* **340**:227, 1999
190. Li N et al: Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. *J Clin Invest* **115**:3440, 2005
191. Czernik A, Beutner EH, Bystryn JC: Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. *J Am Acad Dermatol* **58**:796, 2008
192. Engineer L, Bhol KC, Ahmed AR: Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. *J Am Acad Dermatol* **43**:1049, 2000
193. Ahmed AR, Dahl MV: Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. *Arch Dermatol* **139**:1051, 2003
194. Amagai M et al: A randomized double-blind trial of intravenous immunoglobulin for pemphigus. *J Am Acad Dermatol* **60**:595, 2009
195. Katz KA et al: Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. *Arch Dermatol* **139**:991, 2003
196. Ahmed AR et al: Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. *N Engl J Med* **355**:1772, 2006
197. Guillaume JC et al: Controlled study of plasma exchange in pemphigus. *Arch Dermatol* **124**:1659, 1988
198. Turner MS, Sutton D, Sauder DN: The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. *J Am Acad Dermatol* **43**:1058, 2000
199. Euler HH, Loffler H, Christophers E: Synchronization of plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris. *Arch Dermatol* **123**:1205, 1987
200. Shimanovich I et al: Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. *Clin Exp Dermatol* **31**:768, 2006

201. Werth VP: Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. *Arch Dermatol* **132**:1435, 1996
202. Roujeau JC: Pulse glucocorticoid therapy. The 'big shot' revisited. *Arch Dermatol* **132**:1499, 1996
203. Mentink LF et al: Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. *Arch Dermatol* **142**:570, 2006